The Cancer Survivors Network (CSN) is a peer support community for cancer patients, survivors, caregivers, families, and friends! CSN is a safe place to connect with others who share your interests and experiences.

Thank you for being a part of the Cancer Survivor Network community. Survivors and caregivers like you have played a unique role in fostering an online environment that encourages connection among those needing support, community, and education. On May 28, the Network will be discontinued. More details are available here . If you have any questions, contact CSNSupportTeam@cancer.org. Thanks again for the support you’ve provided each other over the years. We remain committed to supporting you in other ways throughout your cancer journey.

Kanjinti (biosimilar Herceptin drug)

jjtrim
jjtrim CSN Member Posts: 27
in Uterine/Endometrial Cancer #1

Hi All,

 

My mother has just been informed that all patients currently on Herceptin will be switched to this new biosimilar drug, Kanjinti.  It was recently FDA approved for HER2 positive patients on Herecptin.  Kaiser has adopted it and will switch all patients (including breast cancer) to this new drug.  I'm unfamiliar with "biosimilar" drugs but my superficial research says it is nearly identical in efficacy and side effects, and does in fact contain the same ingredient - trastuzumab.  Does anyone have knowledge or experience with this drug?

 

Keeping you all in my thoughts as we forge on.  New drugs and advances all the time. 

 

Thanks everyone,

Jenny

Like Care

Discussion Boards